Athena Athena

X
[{"orgOrder":0,"company":"Legacy Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Legacy Healthcare Announces Positive Top-Line Results from Phase 2\/3 Trial of Coacillium Cutaneous Solution, the First Drug for Children and Adolescents with Moderate and Severe Alopecia Areata","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Legacy Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Legacy Healthcare Announces EMA Validation of Marketing Authorisation Application (MAA) for Coacillium for the treatment of Moderate and Severe Alopecia Areata in Children and Adolescents","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II\/ Phase III"}]

Find Clinical Drug Pipeline Developments & Deals by Legacy Healthcare

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            LH-8 (coacillium) is an investigational botanical drug and is the first and only drug candidate for alopecia areata in children and adolescents with both moderate and severe forms of the disease.

            Lead Product(s): Coacillium

            Therapeutic Area: Dermatology Product Name: LH-8

            Highest Development Status: Phase II/ Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 19, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            LH-8 (coacillium) is an investigational topical botanical drug. Drug interrupts the immuno-inflammatory reactions and their deleterious consequences on hair follicles and adjacent dermal tissues via a pleiotropic mechanism.

            Lead Product(s): Coacillium

            Therapeutic Area: Dermatology Product Name: LH-8

            Highest Development Status: Phase II/ Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 06, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY